Leukemia risk heightened due to high magnetic field exposure

09-11-2006

A higher risk of childhood leukemia, particularly of acute lymphoblastic leukemia (ALL), was linked to high magnetic field (MF) exposure.

According to recent research published in the International Journal of Cancer, "Residential power-frequency MFs were labeled as a possible human carcinogen by the International Agency for Research on Cancer panel. In response to great public concern, the World Health Organization urged that further epidemiologic studies be conducted in high-exposure areas such as Japan."

"We conducted a population-based case-control study, which covered areas inhabited by 54% of Japanese children," explained M. Kabuto and colleagues, National Institute for Environmental Studies. "We analyzed 312 case children (0-15 years old) newly diagnosed with ALL or acute myelocytic leukemia (AML) in 1999-2001 (2.3 years) and 603 controls matched for gender, age and residential area. Weekly mean MF level was determined for the child's bedroom. MF measurements in each set of a case and controls were carried out as closely in time as possible to control for seasonal variation.

"We evaluated the association using conditional logistic regression models. The odds ratios for children whose bedrooms had MF levels of 0.4 mc T or higher compared with the reference category (MF levels below 0.1 mc T) was 2.6 (95% CI=0.76-8.6) for AML + ALL and 4.7 (1.15-19.0) for ALL only. Controlling for some possible confounding factors did not alter the results appreciably. Even an analysis in which selection bias was maximized did not fully explain the association. Most of the leukemia cases in the highest exposure category had MF levels far above 0.4 mc T."

The researchers concluded, "Our results provided additional evidence that high MF exposure was associated with a higher risk of childhood leukemia, particularly of ALL."

Kabuto and colleagues published their study in International Journal of Cancer (Childhood leukemia and magnetic fields in Japan: A case-control study of childhood leukemia and residential power-frequency magnetic fields in Japan. Int J Cancer, 2006;119(3):643-650).

For additional information, contact M. Kabuto, National Institute for Environmental Studies, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.

The publisher's contact information for the International Journal of Cancer is: Wiley-Liss, Division John Wiley & Sons Inc., 111 River St., Hoboken, NJ 07030, USA.

Keywords: Ibaraki, Japan, Carcinogenesis, Case Control Study, Childhood Leukemia, Epidemiology, Japan, Oncology, Pediatric, Population Based, Residential Magnetic Fields, Risk Factor.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.



Related Diseases: Acute Lymphocytic Leukemia (ALL)
Related Resources: Leukemia Research Foundation
Related Glossary Terms: ALL
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds
Some blood-system stem cells reproduce more slowly than expected
Adult survivors of childhood cancer have lower bone mineral density
Mouse model highlights histone methylation as distinguishing feature for leukemia subtypes
Silencing a protein could kill T-Cells, reverse leukemia
Acute Myeloid Leukemia (AML)
Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds
Some blood-system stem cells reproduce more slowly than expected
Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Inhibition of All Known Variants of the CML Target Protein Bcr-Abl
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Fostamatinib Disodium Effective for Diffuse B-Cell Lymphoma and CLL
Some blood-system stem cells reproduce more slowly than expected
Bayer HealthCare Pharmaceuticals (BAY) Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 ASH Annual Meeting
UCSD researchers identify potential new drug target for chronic leukemia
Chronic Myeloid Leukemia (CML)
Some blood-system stem cells reproduce more slowly than expected
ARIAD Presents Preclinical Data on Its Kinase Inhibitor, AP24534, Demonstrating Inhibition of All Known Variants of the CML Target Protein Bcr-Abl
Silencing a protein could kill T-Cells, reverse leukemia
A potential new way to make a good anti-leukemia drug even better
2008 SF Leukemia Cup Regatta - Sailing for Leukemia
Hodgkin Lymphoma
Hodgkin lymphoma -- new characteristics discovered
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
September Is National Leukemia and Lymphoma Awareness Month
Nerve cancer mutations found
Multiple Myeloma
Mozobil™ Approved for Stem Cell Mobilization in NHL and MM Patients
Analysis shows revlimid plus dexamethasone increases overall survival in multiple myeloma patients
Multiple Myeloma Research Foundation's (MMRF) Annual Gala Raises More Than $1.5 Million to Advance Cancer Research
Thalomid® in Induction Improves Progression-free Survival in Elderly with Myeloma
The IMF says journal editorial documents dramatic increase in survival since the 1980s
Myelodysplastic Syndrome (MDS)
New Risk Model for MDS Applies to All Stages of Disease
Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
CHMP Awards Positive Opinion for Myelodysplastic Syndrome Drug
Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS
FDA Approves Vidaza Label Expansion
Non-Hodgkin Lymphoma (NHL)
Mozobil™ Approved for Stem Cell Mobilization in NHL and MM Patients
Addition of Zevalin(R) to Chemotherapy Effective for Follicular NHL
Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
Queen's University Using Xceed Molecular's Ziplex in Follicular Lymphoma Study
Lymphoma 101: Everything you need to know
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer